ZyVersa Therapeutics Announces Board and Executive Changes
Ticker: ZVSA · Form: 8-K · Filed: Oct 15, 2025 · CIK: 1859007
| Field | Detail |
|---|---|
| Company | Zyversa Therapeutics, Inc. (ZVSA) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, governance
TL;DR
ZyVersa's board and execs are changing, impacting future strategy.
AI Summary
ZyVersa Therapeutics, Inc. announced on October 10, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty and signal potential strategic shifts.
Key Players & Entities
- ZyVersa Therapeutics, Inc. (company) — Registrant
- Larkspur Health Acquisition Corp. (company) — Former Company Name
- October 10, 2025 (date) — Date of earliest event reported
- October 15, 2025 (date) — Filing Date
FAQ
What specific roles have been affected by the departures of directors or officers?
The filing indicates departures of certain officers and directors, but does not specify the exact roles in the provided text.
Who are the newly elected directors?
The filing states that directors have been elected, but their names are not provided in this excerpt.
What are the key changes in compensatory arrangements for officers?
The filing mentions updates to compensatory arrangements for certain officers, but the specifics of these arrangements are not detailed in this text.
When was ZyVersa Therapeutics, Inc. formerly known as Larkspur Health Acquisition Corp.?
The date of the name change from Larkspur Health Acquisition Corp. to ZyVersa Therapeutics, Inc. was April 26, 2021.
What is the principal executive office address for ZyVersa Therapeutics, Inc.?
The principal executive offices are located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida 33326.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2025-10-15 16:30:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ZVSA — (1) Indicate by
Filing Documents
- form8-k.htm (8-K) — 34KB
- 0001493152-25-018156.txt ( ) — 195KB
- zvsa-20251010.xsd (EX-101.SCH) — 3KB
- zvsa-20251010_lab.xml (EX-101.LAB) — 33KB
- zvsa-20251010_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Appointment of
Item 5.02 Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 10, 2025, Pablo Guzman, M.D., resigned as Chief Medical Officer and Senior Vice President of Medical Affairs of ZyVersa Therapeutics, Inc. (the "Company"). Dr. Guzman first joined the Company in January 2015, following more than 35 years of practicing medicine/interventional cardiology in South Florida and serving as a managing partner of Cardiology Associates of Fort Lauderdale. Dr. Guzman resigned to spend more time with his family and to travel.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 15, 2025 ZYVERSA THERAPEUTICS, INC. /s/ Stephen Glover Stephen Glover Chief Executive Officer